Lack of efficacy of 5 grams daily of creatine in schizophrenia: a randomized, double-blind, placebo-controlled trial
Kaptsan A, Odessky A, Osher Y, Levine J
The Journal of clinical psychiatry · 7 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2007-06-15 · J Clin Psychiatry · vol. 68 · número 06 · págs. 881–884
- Editorial
- Physicians Postgraduate Press, Inc.
- Citado
- 17 citas · más que el 59% de estudios similares · 0.2× el promedio de su campo
- Referencias
- 27 trabajos
- Acceso
- De pago
- Áreas de investigación
- Schizophrenia research and treatment · Amino Acid Enzymes and Metabolism · Treatment of Major Depression
- Palabras clave
- creatine monohydrate, schizophrenia, dietary supplementation, brain energy metabolism, cognitive enhancement, treatment efficacy, adverse effects, PANSS, cognitive function
- MeSH
- humans, creatine, treatment outcome, cross-over studies, double-blind method, cognition, schizophrenia, psychiatric status rating scales, adult, middle aged, female, male
4 autores
- Alex Kaptsan🇮🇱Ben-Gurion University of the Negev
- Alex Odessky
- Yamima Osher
- Joseph Levine
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
Creatine plays a pivotal role in brain energy homeostasis and has been tried in the treatment of neurologic, neuromuscular, and atherosclerotic disease with a paucity of side effects. Creatine monohydrate supplementation may enhance cognitive functions in healthy subjects. Several independent lines of evidence suggest the possible involvement of altered cerebral energy metabolism in schizophrenia. Creatine effects on brain energy metabolism and its possible cognitive-enhancing properties raise the possibility of developing a new therapeutic strategy in schizophrenia by focusing on treating metabolic hypoactive brain areas including frontal regions.
Method
Twelve schizophrenia patients (DSM-IV criteria) were enrolled into a treatment study with creatine or placebo, and each treatment was administered for 3 months (dosage, 3-5 grams per day) in a randomized, double-blind crossover design. Ten patients completed the study, which was conducted from November 2004 through February 2006. Rating scales included the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions (CGI) scale, scales for the assessment of side effects, and a cognitive battery.
Results
Creatine treatment was not superior to placebo in improving the scores of PANSS, CGI, or the neurocognitive measures administered. Side effects of creatine treatment were few.
Conclusion
Three months of creatine administration failed to detect any efficacy in treating symptoms of schizophrenia, but further research is suggested.
Clinical trials registration
ClinicalTrials.gov identifier NCT00140192.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.